 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AZD2693 / AstraZeneca
P1 data, Journal: AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. (Pubmed Central) - Jan 12, 2025
P1
AZD2693 reduced liver PNPLA3 with an acceptable safety and tolerability profile. These findings support the continued development of AZD2693.
- || AZD2693 / AstraZeneca
Enrollment closed: A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 (clinicaltrials.gov) - Sep 2, 2024
P1, N=35, Active, not recruiting, Sponsor: AstraZeneca
These findings support the continued development of AZD2693. Recruiting --> Active, not recruiting
- || AZD2693 / AstraZeneca
Enrollment closed: FORTUNA: A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (clinicaltrials.gov) - Jun 6, 2024
P2, N=175, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- AZD2693 / AstraZeneca
AZD2693, a potent PNPLA3 antisense oligonucleotide, decreases hepatic PNPLA3 mRNA and liver fat content in participants with presumed MASH and homozygous for the PNPLA3 148M risk allele (Poster Area) - Apr 29, 2024 - Abstract #EASLILC2024EASL_ILC_2707;
- | AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 (clinicaltrials.gov) - Apr 14, 2024
P1, N=36, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- ||| AZD2693 / AstraZeneca
Trial completion: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Jan 17, 2024
P1, N=74, Completed, Sponsor: AstraZeneca
Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024 Active, not recruiting --> Completed
- | AZD2693 / AstraZeneca
Phase classification: FORTUNA: A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (clinicaltrials.gov) - Dec 13, 2023
P2, N=180, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Phase classification: P2b --> P2
- || AZD2693 / AstraZeneca
Enrollment closed: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Aug 14, 2023
P1, N=74, Active, not recruiting, Sponsor: AstraZeneca
Phase classification: P2b --> P2 Recruiting --> Active, not recruiting
- || AZD2693 / AstraZeneca
Enrollment open: A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 (clinicaltrials.gov) - Jul 6, 2023
P1, N=32, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || AZD2693 / AstraZeneca
New P1 trial: A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 (clinicaltrials.gov) - Jun 26, 2023
P1, N=36, Not yet recruiting, Sponsor: AstraZeneca
- || AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Jun 15, 2023
P1, N=74, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
- || AZD2693 / AstraZeneca
Trial completion: Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (clinicaltrials.gov) - Apr 20, 2023
P1, N=44, Completed, Sponsor: AstraZeneca
Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024 Active, not recruiting --> Completed
- |||||| AZD2693 / AstraZeneca
New P2b trial: FORTUNA: A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (clinicaltrials.gov) - Apr 12, 2023
P2b, N=232, Recruiting, Sponsor: AstraZeneca
- || AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Nov 4, 2022
P1, N=80, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023
- || AZD2693 / AstraZeneca
Enrollment closed: Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (clinicaltrials.gov) - Oct 31, 2022
P1, N=44, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023 Recruiting --> Active, not recruiting
- ||| AZD2693 / AstraZeneca, ION455 / Ionis, AstraZeneca
Does not bode well for NASH assets ION839 and ION455🤔 🤞 (Twitter) - Sep 24, 2022
- ||||| AZD2693 / AstraZeneca
Clinical: It took us a while to randomize but my research nurse was relentless in her pursuit…AZD2693/placebo being delivered SQ to lower the mRNA expression of PNPLA3. Personalized treatment of NASH based on genetics!! @DrLoomba @NoureddinMD @AlkhouriNaim @ajay_duseja @nagachalasani (Twitter) - Aug 3, 2022
- || AZD2693 / AstraZeneca
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (clinicaltrials.gov) - Aug 3, 2022
P1, N=44, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=22 --> 44 | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- || AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Jul 28, 2022
P1, N=67, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting | N=22 --> 44 | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jan 2023 --> Jun 2023
- || AZD2693 / AstraZeneca
Enrollment closed: Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (clinicaltrials.gov) - Apr 25, 2022
P1, N=22, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jan 2023 --> Jun 2023 Recruiting --> Active, not recruiting
- || AZD2693 / AstraZeneca
Enrollment open: Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (clinicaltrials.gov) - Dec 28, 2021
P1, N=22, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| AZD2693 / AstraZeneca
Trial completion: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Nov 26, 2021
P1, N=73, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || AZD2693 / AstraZeneca
New P1 trial: Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (clinicaltrials.gov) - Nov 4, 2021
P1, N=22, Not yet recruiting, Sponsor: AstraZeneca
- || AZD2693 / AstraZeneca
Enrollment closed: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Aug 10, 2021
P1, N=73, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Feb 10, 2021
P1, N=52, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial completion date: Sep 2021 --> Aug 2022 | Trial primary completion date: Sep 2021 --> Aug 2022
- || AZD2693 / AstraZeneca
Enrollment change: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Jan 15, 2021
P1, N=79, Recruiting, Sponsor: AstraZeneca
Trial completion date: Sep 2021 --> Aug 2022 | Trial primary completion date: Sep 2021 --> Aug 2022 N=48 --> 79
- ||| AZD2693 / AstraZeneca
Enrollment open: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Dec 3, 2020
P1, N=52, Recruiting, Sponsor: AstraZeneca
N=48 --> 79 Not yet recruiting --> Recruiting
- || AZD2693 / AstraZeneca
Enrollment change: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Oct 19, 2020
P1, N=48, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=76 --> 48
- || AZD2693 / AstraZeneca
Enrollment change: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Sep 28, 2020
P1, N=76, Recruiting, Sponsor: AstraZeneca
N=76 --> 48 N=115 --> 76
- || AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Aug 21, 2020
P1, N=115, Recruiting, Sponsor: AstraZeneca
N=115 --> 76 Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021
- || AZD2693 / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Jul 23, 2020
P1, N=115, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021 N=49 --> 115 | Trial completion date: May 2021 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021
- ||| AZD2693 / AstraZeneca
New P1 trial: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (clinicaltrials.gov) - Jul 22, 2020
P1, N=60, Not yet recruiting, Sponsor: AstraZeneca
- | AZD2693 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Feb 5, 2020
P1, N=49, Recruiting, Sponsor: AstraZeneca
N=49 --> 115 | Trial completion date: May 2021 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021 Trial completion date: Nov 2020 --> May 2021 | Trial primary completion date: Nov 2020 --> May 2021
- || AZD2693 / AstraZeneca
Enrollment open: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Nov 20, 2019
P1, N=48, Recruiting, Sponsor: AstraZeneca
Trial completion date: Nov 2020 --> May 2021 | Trial primary completion date: Nov 2020 --> May 2021 Not yet recruiting --> Recruiting
- || AZD2693 / AstraZeneca
New P1 trial: A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (clinicaltrials.gov) - Nov 4, 2019
P1, N=48, Not yet recruiting, Sponsor: AstraZeneca